

# **I. OVERVIEW OF THE FUNDING OPPORTUNITY**

**Program Announcement for the Department of Defense**

**Defense Health Program**

**Congressionally Directed Medical Research Programs**

**Peer Reviewed Alzheimer’s Research Program**

**Transforming Research Award**

**Announcement Type: Initial**

**Funding Opportunity Number: HT942524PRARPTTrRA**

**Assistance Listing Number: 12.420 Military Medical  
Research and Development**

## **SUBMISSION AND REVIEW DATES AND TIMES**

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern time (ET), May 22, 2024
- **Application Submission Deadline:** 11:59 p.m. ET, June 20, 2024
- **End of Application Verification Period:** 5:00 p.m. ET, June 26, 2024
- **Peer Review:** August 2024
- **Programmatic Review:** October 2024

*This program announcement must be read in conjunction with the General Application Instructions, version 901. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”*

## TABLE OF CONTENTS

<b>I.</b>	<b>OVERVIEW OF THE FUNDING OPPORTUNITY.....</b>	<b>1</b>
<b>II.</b>	<b>DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY.....</b>	<b>3</b>
II.A.	Program Description.....	3
II.B.	Award Information .....	3
II.C.	Eligibility Information.....	7
II.C.1.	Eligible Applicants .....	7
II.C.2.	Cost Sharing.....	8
II.C.3.	Other .....	8
II.D.	Application and Submission Information.....	8
II.D.1.	Location of Application Package .....	8
II.D.2.	Content and Form of the Application Submission .....	9
II.D.2.a.	Step 1: Pre-Application Submission .....	10
II.D.2.b.	Step 2: Full Application Submission .....	11
II.D.2.c.	Applicant Verification of Full Application Submission in eBRAP .....	23
II.D.3.	Unique Entity Identifier (UEI) and System for Award Management (SAM) .....	23
II.D.4.	Submission Dates and Times.....	24
II.D.5.	Funding Restrictions.....	24
II.D.6.	Other Submission Requirements .....	25
II.E.	Application Review Information .....	25
II.E.1.	Criteria .....	25
II.E.2.	Application Review and Selection Process.....	28
II.E.3.	Integrity and Performance Information.....	29
II.F.	Federal Award Administration Information .....	29
II.F.1.	Federal Award Notices.....	29
II.F.2.	PI Changes and Award Transfers.....	30
II.F.3.	Administrative and National Policy Requirements.....	30
II.F.4.	Reporting.....	31
II.G.	Federal Awarding Agency Contacts.....	32
II.G.1.	eBRAP Help Desk.....	32
II.G.2.	Grants.gov Contact Center .....	32
II.H.	Other Information.....	32
II.H.1.	Program Announcement and General Application Instructions Versions.....	32
II.H.2.	Administrative Actions.....	32
II.H.3.	Full Application Submission Checklist.....	35
<b>APPENDIX 1:</b>	<b>ACRONYM LIST .....</b>	<b>37</b>

## **II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY**

### **II.A. Program Description**

The U.S. Army Medical Research Acquisition Activity (USAMRAA) is soliciting applications to the fiscal year 2024 (FY24) Peer Reviewed Alzheimer's Research Program (PRARP) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC) is the program management agent for this funding opportunity. Congress initiated the PRARP in 2011 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the PRARP from FY11 through FY23 totaled \$183 million (M). The FY24 appropriation is \$15M.

Consistent with the PRARP's mission and vision, the program seeks to support transformative research on the intersection of traumatic brain injury (TBI) and Alzheimer's disease (AD) and related dementias (ADRD). There is an urgent need to prevent and reduce the risk of developing AD/ADRD, particularly following TBI and other deleterious exposures. Active-duty and former military personnel are at increased risk of developing dementia following their service. The PRARP encourages innovation to accelerate research and interventions in the risk reduction and prevention space.

The PRARP emphasizes that the outcomes of PRARP-funded research should be applicable to all and are representative of the populations they aim to benefit.

### **II.B. Award Information**

The FY24 PRARP TrRA is intended to support studies that will make transformative and advanced contributions to reduce risk of or prevent the development of AD/ADRD. Risk reduction considering TBI and/or military service is of particular interest to the program. The work should significantly accelerate efforts in AD/ADRD research and demonstrate significant impact toward improving patient care and/or quality of life.

To meet the intent of the funding opportunity, applications must robustly address an important problem or a critical barrier to progress in prevention and risk reduction. The proposed research may include, but is not limited to, exploring questions in the following areas:

- Identification of risk factors (environmental, genetic, epigenetic, lifestyle, etc.).
- Identification and implementation of strategies to reduce AD/ADRD risk and prevent cognitive problems following TBI and/or military service.
- Understanding the role of social determinants of health in risk reduction.
- Informational (not descriptive) epidemiology to understand environmental and other factors that contribute to development of AD/ADRD.

***All applications submitted to this funding opportunity must clearly indicate how the project addresses a critical unmet need, explain how the research will be representative of the population it intends to benefit, and demonstrate cultural competence.*** Culturally competent research factors the cultural background and diversity of the intended beneficiaries of the research outcomes when developing research ideas, conducting research, and implementing the research findings. Cultural competency in research is critical in reducing health disparities and enhancing the quality and impact of research by ensuring inclusivity, understanding, and responsiveness to the needs of diverse populations.

**Key elements of this award mechanism include:**

- **Research should be robust:** The FY24 PRARP TrRA mechanism is geared toward supporting robust, well-designed research projects that provide significant impact on the AD/ADRD field, persons living with dementia, and their families, care-partners/caregivers. Inclusion of collaborative Community partner approaches is strongly encouraged for all projects and is *required for all projects involving clinical research*. **Use of animal models must be fully justified for relevance to human health.**
- **Non-incremental advancement:** Research projects should leverage existing knowledge to accelerate ideas, strengthen evidence, and move the field forward. Therefore, *preliminary data are required*. Projects proposing incremental advances that do not significantly propel the field do not meet the intent of this mechanism.
- **Feedback to the Community:** Applicants are expected to articulate *a plan for relaying the results and outcomes of the research* supported by this mechanism must be relayed back to the research/Community(ies) to allow for continued knowledge building.
- **Optimizing research impact through Community collaboration:** Research funded by the FY24 PRARP should be responsive to the needs of people living with AD/ADRD. Community collaboration is required for clinical research projects and encouraged for preclinical studies. Establishment and utilization of effective and equitable collaborations and partnerships with members of the AD/ADRD lived experience, family, and care partner communities, which will be referred to as Community(ies) in the remainder of the Funding Opportunity, maximizes the translational and impact potential of the proposed research.

Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of Community members within the research team. Collaborative research approaches such as Community-based participatory research, participatory action research, and integrated knowledge transition generate partnerships between scientific researchers and Community members to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and Community members must collaborate and contribute their expertise equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Research results are jointly interpreted, disseminated, fed back to affected communities, and may be translated into interventions or policy. These methods are critically important for

Community-level interventions and can also augment the potential impact of a research program on people living with dementia, their families, and/or their care partners.

These collaborative relationships are often established through integrating Community members into research teams as co-researchers, advisors, and consultants. Some examples for Community collaborations include:

- **Lived Experience Consultation:** The research team includes at least one project advisor with AD/ADRD experience who will integrate with the research team to provide consultation throughout the planning, implementation, and dissemination of the research project. Lived experience consultants (LECs) may include individuals with AD/ADRD, their family members, care partners, or others as appropriate.
- **Partnership with a Community-Based Organization:** The research team establishes partnerships with at least one Community-based organization that provides consultation throughout the planning, implementation, and dissemination of the research project. Community-based organizations may include advocacy groups, service providers, policymakers, or other formal organizational stakeholders.
- **Community Advisory Board (CAB) Utilization:** A CAB is composed of multiple Community stakeholders and can take many forms, from a board of LECs to a coalition of Community-based organizations or any combination thereof. As with LECs and organizational partners, the CAB provides consultation throughout the planning, implementation, and dissemination of the research project.

**Career Initiation or Transition (CIT) Partnership Option:** The FY24 PRARP encourages applications that include meaningful and productive collaborations between two principal investigators. To promote enhanced research capacity within the AD/ADRD field, the FY24 TrRA includes an option for a CIT Principal Investigator (PI) to partner with an experienced investigator to jointly address a research question.

The CIT PI must have nominal, if any, research support in the field and may be either one of the following:

1. The **Career Initiation** PI must be an early-career researcher, at least 3 years post their terminal degree but no more than 7 years into their independent position. Both PIs may have similar or disparate expertise, but each PI is expected to bring distinct and complimentary contributions to the application.
2. The **Career Transition** PI must be an investigator (at any stage) who is new to the military health, TBI, or AD/ADRD field(s). “New to the field” is defined as having only nominal, if any, publications in the field. The other partnering investigator must have complimentary experience (as evidenced by publications) in military health, TBI, and/or AD/ADRD field(s).

The CIT is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for most of the administrative tasks associated with application submission. The other will be identified as a Partnering PI. Either PI can be the CIT PI. Both PIs should

contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. Both PIs may have experience in similar or disparate scientific disciplines, but each PI is expected to bring distinct and complimentary contributions to the application. If recommended for funding, each PI will be named to an individual award within the recipient organization(s). For individual submission requirements for the Initiating and Partnering PI, refer to [Section II.D.2, Content and Form of the Application Submission](#).

#### **Additional Considerations:**

CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.

***Clinical trials are not allowed under this funding opportunity.***

***A clinical trial is defined*** in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

***Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.***

***For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research*** encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:

(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does ***not*** seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.

(2) Epidemiologic and behavioral studies that do ***not*** seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.

(3) Outcomes research and health services research that do not fit under the definition of clinical trial.

Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under [§46.104\(d\)\(4\) of the Common Rule](#).

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

The anticipated total costs budgeted for the entire period of performance for an FY24 PRARP TrRA should not exceed **\$1.0M**. Refer to [Section II.D.5, Funding Restrictions](#), for detailed funding information.

Awards supported with FY24 funds will be made no later than September 30, 2025.

*The CDMRP expects to allot approximately \$5.0M to fund approximately five Transforming Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.*

## **II.C. Eligibility Information**

### **II.C.1. Eligible Applicants**

**II.C.1.a. Organization:** Extramural and Intramural organizations are eligible to apply, including foreign or domestic organizations, for-profit and non-profit organizations, and public entities.

**Extramural Organization:** An eligible non-Department of Defense (DOD) organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD (i.e., intragovernmental organizations), and research institutes.

**Intramural DOD Organization:** Refers specifically to DOD organizations including DOD laboratories, DOD military treatment facilities, and/or DOD activities embedded within a civilian medical center.

Awards are made to eligible *organizations*, not to individuals. Refer to the General Application Instructions, Appendix 1, for additional recipient qualification requirements.

### **II.C.1.b. Principal Investigator**

Independent investigators at all career levels may be named by the organization as the PI on the application.

**Career Initiation or Transition (CIT) Partnering PI Option:** CIT investigators should have nominal, if any, research support in the field. Career initiation investigators must have at least 3 years research experience beyond a terminal degree but no more than 7 years within their first independent research position. Career transition investigators may be any level, but new to

military health, TBI, and/or AD/ADRD fields, with nominal, if any, publications for their intended field. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

### **II.C.2. Cost Sharing**

Cost sharing/matching is not an eligibility requirement.

### **II.C.3. Other**

Organizations must be able to access **.gov** and **.mil** websites to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

Refer to [Section II.H.2, Administrative Actions](#), for a list of administrative actions that may be taken if a pre-application or full application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

## **II.D. Application and Submission Information**

### **II.D.1. Location of Application Package**


Submission is a two-step process requiring both a *pre-application* submitted via the Electronic Biomedical Research Application Portal (eBRAP.org) and a *full application* (eBRAP.org or Grants.gov). Depending on the type of submission (i.e., extramural vs. intramural), certain aspects of the submission process will differ.

The CDMRP uses two portal systems to accept pre- and full application submissions.

**eBRAP** (<https://ebrap.org>) is a secure web-based system that allows PIs and/or organizational representatives from both extra- and intramural organizations to receive communications from the CDMRP and submit their pre-applications. Additionally, eBRAP allows extramural applicants to view and verify full applications submitted to Grants.gov and allows intramural DOD applicants to submit and verify full applications following their pre-application submission.



**Grants.gov** (<https://grants.gov>) is a federal system that must be used by funding agencies to announce extramural grant applications. Full applications for CDMRP funding opportunities can only be submitted to Grants.gov after submission of a pre-application through eBRAP.



**Extramural Submission:** An application submitted by an [extramural organization](#) for an extramural or intramural PI working within an extramural or intramural organization. For example, a research foundation submitting an application for a DOD employee working within a DOD organization would be considered an extramural submission and should follow instructions specific to extramural submissions.) Download application package components for HT942524PRARPTTrRA from Grants.gov (<https://grants.gov>). Full applications from extramural organizations **must** be submitted through Grants.gov.

**Intramural Submission:** An application submitted by an [intramural DOD organization](#) for an investigator employed by that organization. Intramural DOD organizations **may** submit full applications to either eBRAP or Grants.gov. Download application package components for HT942524PRARPTTrRA from the anticipated submission portal eBRAP (<https://ebrap.org>) or Grants.gov.

The submission process should be started early to avoid missing deadlines. Regardless of submission type or portal used, all pre- and full application components must be submitted by the deadlines stipulated on the first page of this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The USAMRAA cannot make allowances/exceptions for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.***

## II.D.2. Content and Form of the Application Submission

***Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).***

Unnecessary duplication of funding, or accepting funding from more than one source for the same research, is prohibited. See CDMRP's full position on research duplication at <https://cdmrp.health.mil/funding/researchDup>.

Including classified research data within the application and/or proposing research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns, may result in application withdrawal. Refer to the General Application Instructions, Appendix 7, Section B.

FY24 PRARP Programmatic Panel members should not be involved in any pre-application or full application. For questions related to panel members and pre-applications or applications, refer to [Section II.H.2.c, Withdrawal](#), or contact the eBRAP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507.

### **II.D.2.a. Step 1: Pre-Application Submission**

All pre-application components must be submitted by the PI and Initiating PI through eBRAP (<https://eBRAP.org/>), including the submission of contact information for the Partnering PI if exercising the **Career Initiation or Transition Partnering PI Option**.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title, and all information for each PI, the Business Official(s), performing organization(s), and contracting organization(s) must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507 prior to the application submission deadline.

**Career Initiation or Transition Partnering PI Option:** After the Initiating PI confirms submission of the pre-application, the Partnering PI will be notified of the pre-application submission via an email from eBRAP. *The Partnering PI must follow the link in the notification email to associate the partnering pre-application with their eBRAP account.* If not previously registered, the Partnering PI must register in eBRAP.

After associating the pre-application with their eBRAP account, the Partnering PI should email the eBRAP Help Desk ([help@ebrap.org](mailto:help@ebrap.org)) to have the desired contact information associated with their pre-application. The email should include the pre-application log number, the name of the Business Official, the name(s) of the Performing/Contracting Organization(s), and the submission-type for the pre-application (extramural or intramural).

*The Partnering PI should not initiate a new pre-application based on the same research project submitted by the Initiating PI.* The Partnering PI is urged to complete these steps as soon as possible. If they are not completed:

- The Partnering PI will not be able to view and modify their full application during the verification period in eBRAP.

- An intramural Partnering PI will not be able to submit their full application package components to eBRAP.

When starting the pre-application, applicants will be asked to select a “Mechanism Option”. Please be sure to select the correct option appropriate to your pre-application:

Applicant	eBRAP Mechanism Option
Single PI	No Option
Initiating PI (Career Initiation or Transition Partnering PI Option)	Partnering PI

### II.D.2.a.i. Pre-Application Components

Pre-application submissions must include the following components (refer to the General Application Instructions, Section III.B, for detailed instructions regarding pre-application submission):

- **Letter of Intent (LOI) (one-page limit):** Provide a brief description of the research to be conducted, including the topic, and approach. Indicate whether study participants, human biospecimens, and/or data will be utilized. **Briefly describe the Community collaboration, if applicable, including names of individuals participating.**
- LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review. *An invitation to submit a full application is NOT provided after LOI submission. Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.*

### II.D.2.b. Step 2: Full Application Submission

#### II.D.2.b.i. Full Application Submission Type

**Extramural Submissions:** Full applications from extramural organizations *must* be submitted through Grants.gov Workspace. Full applications from extramural organizations, including non-DOD federal organizations, received through eBRAP will be withdrawn. Refer to the General Application Instructions, Section IV, for considerations and detailed instructions regarding extramural full application submission.

**Intramural Submissions:** Intramural DOD organizations may submit full applications through either eBRAP or Grants.gov. There is no preference from the CMDRP for which submission portal is utilized; submission through one portal or the other does not provide the application any advantage during the review process. Intramural DOD organizations that choose to submit through Grants.gov should follow Extramural Submission instructions. Intramural DOD organizations that are unable to submit through Grants.gov should submit through eBRAP. For the remainder of this program announcement, it will be assumed intramural DOD submissions will proceed through eBRAP. Refer to the General Application Instructions, Section V, for considerations and detailed instructions regarding intramural DOD full application submission.

## II.D.2.b.ii. Full Application Submission Components

**Career Initiation or Transition Partnership Option:** The CDMRP requires separate full application package submissions for the Initiating PI and Partnering PI, even if the PIs are located within the same organization. Each full application package must be submitted using the unique eBRAP log number received by the Initiating and Partnering PIs during pre-application submission. *All associated applications (the Initiating PI's and the Partnering PI's) must be submitted by the full application submission deadline.*

Each application submission must include the completed full application package for this program announcement. See [Section II.H.3](#) of this program announcement for a checklist of the required application components.

**(a) SF424 Research & Related Application for Federal Assistance Form (*Extramural Submissions Only*):** Refer to the General Application Instructions, Section IV.B, for detailed information.

### **(b) Attachments:**

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 2.

- **Attachment 1: Project Narrative (12-page limit): Upload as “ProjectNarrative.pdf”.** The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information that expands the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below. Studies prospectively recruiting human patients must append an inclusion enrollment report (see [Attachment 2, Supporting Documentation](#)). If animal subjects are to be used, [Attachment 9, Animal Research Plan](#), is required.

- **Background/Rationale:** Present the ideas and scientific rationale behind the proposed research project. Cite relevant literature and demonstrate how this research leverages existing knowledge. Demonstrate how this research represents a non-incremental advance upon the existing knowledge.
- **Objective/Specific Aims:** Clearly state the objective(s) to be reached. Concisely explain the project's specific aims. If the proposed research project is part of a larger study, *present only tasks that this PRARP award would fund.*
- **Preliminary Data:** Clearly demonstrate that there is sufficient evidence to support the proposed stage of research. Provide preliminary data to support the proposed

research and endpoints to be measured. Preliminary data may come from the PI's published work or pilot data.

- **Research Strategy and Feasibility:** Describe the research strategy, study design, methods, and analyses, including appropriate controls, in sufficient detail for evaluation of their appropriateness and feasibility. Detail how the research strategy provides a robust, well-designed, and culturally competent approach to non-incremental research that is relevant to the intended population.
  - Describe all measures to reduce bias, such as descriptions of how researchers, subjects, clinicians, data analysts, and/or others will be blinded during the study and other measures.
  - Identify potential problem areas and present alternative methods and approaches.
  - For studies including animals, [Attachment 9](#) is required.
  - For all human study participants, human anatomical samples, or human data projects, describe the strategy to ensure the study populations are representative, equitable, diverse, and inclusive. Describe the composition of the proposed study population in terms of sex/gender, racial, ethnicity, culture, geography, etc., and measures of health equity and social determinants of health. Provide a strong accompanying rationale for the selection of subjects and how well they represent the end beneficiaries of the research.
  - If prospectively collected human anatomical samples or data will be used, include a detailed plan for the recruitment of the subjects or the acquisition of samples or data.
  - If applicable, specify the approximate number of human subjects to be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Describe the availability of the proposed study population and past successes in recruiting similar populations. Explain how proposed clinical research might affect the daily lives of the individual human subjects participating in the study.
  - Outline the process for seeking informed consent and describe the safeguards that are in place for vulnerable populations, if applicable.
  - If active-duty military, military Families, and/or Veteran populations or datasets will be used in the proposed research project, detail the strategy and feasibility of accessing the population(s)/dataset(s). Describe any required data sharing, memorandum of understanding, or other agreements required to access and publish data. A letter confirming support or access is required in [Attachment 2](#).
  - Describe the ethical implications and considerations of the clinical research strategy, including whether the population selected to participate in the study stands to benefit from the knowledge to be gained as a result of the proposed

research, how the level of risk to human subjects is minimized, what safety monitoring and reporting measures are taken for the level of risk.

- **Statistical Plan and Data Analysis:** Describe the statistical model and data analysis plan with respect to the study objectives. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study and all proposed correlative studies. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study.
  - Describe plans for the valid analysis of group differences on the basis of sex/gender, race, and/or ethnicity as appropriate for the scientific goals of the study. Ensure sufficient information is provided to allow thorough evaluation of all statistical calculations during review of the application.
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** Start each document on a new page. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

*There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.*

- **References Cited:** List the references cited (including URLs, if available) in the Project Narrative using a standard reference format.
- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.
- **Inclusion Enrollment Report only required if clinical research is proposed:** provide an anticipated enrollment table(s) for the inclusion of women and minorities appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The Public Health Service (PHS) Inclusion Enrollment Report is a three-page fillable PDF form, which can be downloaded from eBRAP at <https://ebrap.org/eBRAP/public/Program.htm>. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement.
- **Quad Chart:** Provide a Quad Chart for the proposed project. The format for the quad chart is available on the eBRAP “Funding Opportunities & Forms” web page at <https://ebrap.org/eBRAP/public/Program.htm>.
- **Data and Research Resources Sharing Plan:** Describe the type of data or research resource to be made publicly available as a result of the proposed work. Describe

how data and resources generated during the performance of the project will be shared with the research Community. Include the name of the repository(ies) where scientific data and resources arising from the project will be archived, if applicable. If a public repository will not be used for data or resource sharing, provide justification. Provide a milestone plan for data/results dissemination including when data and resources will be made available to other users, including dissemination activities with a particular focus on feeding back the data to affected communities and/or research participants. Refer to CDMRP's Policy on Data & Resource Sharing located on the eBRAP "Funding Opportunities & Forms" web page <https://ebrap.org/eBRAP/public/Program.htm> for more information about CDMRP's expectations for making data and research resources publicly available.

- **Facilities, Existing Equipment, and Other Resources (two-page limit is recommended):** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Organizational Support (one-page limit per letter is recommended):** Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.
- **Letters of Collaboration (if applicable) (two-page limit per letter is recommended):** Provide a signed letter from each collaborating individual and/or organization demonstrating that the PI has the support and resources necessary for the proposed work. If an investigator at an intramural DOD organization is named as a collaborator on a full application submitted through an extramural organization, the application must include a letter from the collaborator's Commander or Commanding Officer at the intramural DOD organization authorizing the collaborator's involvement.

**Use of DOD/U.S. Department of Veterans Affairs (VA) Resources (if applicable):** Provide a signed letter of support confirming access for the entire period of performance to active-duty military population, VA patients, and/or VA/DOD resources, databases, or research space. Provide any additional details regarding data sharing or other agreements needed here.



- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** The technical abstract is used by all reviewers. *Abstracts of all funded research projects will be posted publicly.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Technical abstracts should be written using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project.
- **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached.
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Experimental Design:** Briefly describe the experimental design, including appropriate controls.
- **Impact:** Briefly describe how the proposed research project, if successful, will make transformative and impactful contribution(s) to AD/ADRD and TBI research fields, patient care, and/or quality of life. Briefly describe the innovation of the research.

- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers, and addresses issues of particular interest to the affected community. *Abstracts of all funded research projects will be posted publicly.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. *Do not duplicate the technical abstract.*

Lay abstracts should address the points outlined below. The lay abstract is an important component of the application review process because it addresses issues of particular interest to lived experience subject matter experts (consumers). It is important that the abstract be written in a manner that will be *readily understood by the general public, especially those without a background in science or medicine.*

- Summarize the objectives and rationale for the proposed research.
- What population will the research help, and how will it help them?
- What are the potential applications, benefits, and risks of the anticipated outcomes?
- What are the likely contributions of the proposed research project to advancing research, patient care, and/or quality of life?



- **Attachment 5: Statement of Work (five-page limit): Upload as “SOW.pdf”.** Refer to the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) for the suggested SOW format and recommended strategies for assembling the SOW.

Use the “Suggested SOW Format” to develop the SOW for the proposed research. Submit as a PDF.

- For FITBIR-eligible research include (a) FITBIR investigator and study registration within the first 30 days of the award, (b) sharing of draft data collection forms with FITBIR, (c) annual FITBIR data submissions.
- **Career Initiation or Transition Partnering PI Option: *Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and the Partnering PI should be noted for each task.***

- **Attachment 6: Impact Statement (two-page limit): Upload as “Impact.pdf”.** The Impact Statement is considered by all reviewers on the both the peer and programmatic review panels, and it is important that this attachment be written in a manner that will be *readily understood by the general public, especially those without a background in science or medicine.* Do not use jargon.

Applications should clearly detail the short- and long-term impact of the proposed research outcomes **as though the proposed project is successful in all its aims.**

- How does the project robustly address an important problem or a critical barrier to prevention and risk reduction, and how this is a non-incremental advance that results in change?
- If the aims of the project are successful, how and when will scientific knowledge, technical capability, clinical practice, and/or dementia care be improved and communicated to the research and lived experience communities?
- What immediate and potential long-term benefit(s) does successful completion of this project yield for persons living with TBI and/or AD/ADRD, their families and care partners/caregivers?
- What potential issues that might limit or lessen the impact of the proposed research, and what strategies could overcome those issues?

- **Attachment 7: Progression Plan (two-page limit): Upload as “Progression.pdf”.** For FY24, the PRARP requires all applicants to contemplate and provide a plan outlining a practical trajectory to implementation for the research they are proposing, and how this will ultimately translate to benefit the intended recipients.

Applicants should identify what are the next immediate logical steps following the research proposed in this application and consider how those steps would be successfully achieved.

- Describe the scientific study that would be required **for the immediate next logical step** and include:
  - The timeline with defined milestones needed for that next step to progress toward application and implementation of the research. If this step is immediately executable for clinical or Community use, describe what is needed next to implement. If another research project is required, describe why this additional study is needed and whether that will bring the outcomes to a stage ready to execute and implement.
  - Describe the scientific, technical, and/or regulatory requirements needed to advance the research findings. Include steps necessary for regulatory approval, as applicable. Include steps necessary for Food and Drug Administration regulatory approval, as applicable.
  - Describe collaborations and other resources that will be used to help progress the continuity of research to the next stage of development or clinical implementation (e.g., clinical partners, commercial partners, manufacturing partners, clinical practice guideline development/execution committees, training providers/resources). Include considerations of intellectual property and commercialization plans, as applicable here.
- For the subsequent steps, **describe how feedback from the AD/ADRD/TBI Community will be integrated** into the progression of this research. Outline the plan for disseminating the knowledge to the research, lived experience, clinical, and care communities.
- **Attachment 8: Community Collaboration Plan (if applicable; required for all applications proposing clinical research): Combine and upload as a single file named “Collaboration.pdf”.** Refer to [Section II.B](#) for more details regarding the Community collaboration requirement. This attachment must be written in a manner that will be *readily understood by the general public, especially those without a background in science or medicine*.
- **Collaborative Research Statement (suggested three-page limit):** Include the names of at least one Community partner (e.g., LEC, representative of Community-based organization) who will provide advice and consultation throughout the planning and implementation of the research.
  - Describe the collaborative research approach that will be used (e.g., Lived Experience Consultation, partnership with Community-based organization, CAB, co-researcher model) including a justification for the approach as well as when the approach will be used within the research project. Detail how this best serves your Community/intended user base.
  - Describe how the Community collaborator(s) are connected to your study population(s).

- Indicate the input from the partner that has been or will be captured and how this input will be meaningfully integrated and incorporated into the needs assessment, planning, design, execution, analysis, and dissemination of the research.
  - Describe the resource allocation, decision-making, and equitable participation processes to be employed.
  - Describe any training, co-learning, or capacity-building activities that will be provided to both scientific researchers and Community members on collaborative research approaches, decision-making, and equitable participation.
  - Describe the process measures used to assess the effectiveness of the chosen collaborative approach.
- **Letters of Community Collaboration (suggested two-page limit per letter):** Provide a letter signed by each Community partner confirming their role and commitment to participate on the research team. If a Community-based organization will be engaged, the letter of commitment should be signed by BOTH the organization point of contact leading the engagement and the organization’s leadership endorsing the collaboration. The letter should include a mention of why the qualifications and background of the individual will benefit the proposed research project.
- **Attachment 9: Animal Research Plan (four-page limit): Upload as “Animal.pdf”.** (*Attachment 9 is only applicable and required for applications that are using animal models.*) When the proposed study involves animals, the applicant is required to submit a plan describing the animal research that will be conducted. Applicants should not submit a verbatim replica of the protocol(s) to be submitted to the Institutional Animal Care and Use Committee (IACUC) as the Animal Research Plan, nor should this replicate the Project Narrative. The Animal Research Plan should address additional information needed to fully explain the models and procedures for the proposed animal study:
    - Briefly describe the research objective(s) of the animal study.
    - Explain how and why the animal species, strain, and model(s) being used can and is necessary and appropriate to address the scientific objectives of the proposed research project.
    - Explain why the specific animal AD/ADRD and/or TBI model was chosen over other models and how it is the optimal model for addressing the study aims.
    - Provide clear and strong justification for the specific animal model’s relevance to human TBI and/or AD/ADRD. Explain how the chosen animal model(s) is validated and well-justified in the literature.
    - Summarize the procedures to be conducted, including methods to enhance research rigor, and how the study will be statistically controlled.

- Describe approaches that will be undertaken to validate or corroborate findings from animal studies to relevant human data sources/populations. This could include, but is not limited to, validation of animal transcriptomic data using publicly available human transcriptomic datasets, confirmation of histological findings in a human postmortem case series, and validation against fluid-based or imaging biomarkers.
  - Describe what approach(es) will be used to de-risk the possibility the animal findings may not translate to human populations.
  - **Attachment 10: Partnership Statement (one-page limit): Upload as “Partnership.pdf”.** (*Attachment 10 is only applicable and required for applications submitted under the Career Initiation or Transition Partnering PI Option.*) Describe the experience of the Initiating and Partnering PIs. Describe the contribution and the time commitment of each PI toward the proposed research project and indicate how the award will help to enhance research capacity in the TBI and/or AD/ADRD fields. Describe how the partners’ combined experience will better address the research question and explain why the work should be done together rather than through separate efforts.
  - **Attachment 11: Representations (Extramural Submissions Only): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the Required Representations template available on eBRAP (<https://ebrap.org/eBRAP/public/Program.htm>). For more information, see the General Application Instructions, Appendix 8, Section B, Representations.
  - **Attachment 12: Suggested Intragovernmental/Intramural Budget Form (if applicable): Upload as “IGBudget.pdf”.** If an [intramural DOD organization](#) will be a collaborator in performance of the project, complete a separate budget using the “Suggested Intragovernmental/Intramural Budget Form”, available for download on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>). The budget should cover the entire period of performance for each intramural DOD site and include a budget justification as instructed. The *total* costs per year for each subaward (direct and indirect costs) should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section V.A.(e), for additional information and considerations.
- (c) Research & Related Personal Data:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(c), and for intramural submissions, refer to the General Application Instructions, Section V.A.(c), for detailed instructions.
- (d) Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions, refer to the General Application Instructions, Section IV.B.(d), and for intramural submissions, refer to the General Application Instructions, Section V.A.(d), for detailed instructions.
- **PI Biographical Sketch (five-page limit):** Upload as “Biosketch\_LastName.pdf”.

- **Career Initiation or Transition Partnering PI:** If the CIT PI is the *Initiating PI*, explain how their level of research support and/or publications supports their eligibility.
  - **PI Previous/Current/Pending Support (no page limit):** Upload as “Support\_LastName.pdf”.
  - **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch\_LastName.pdf”.
    - Biographical sketches, or an equivalent document, should also be included for Community partners (e.g., LEC, representative of Community-based organization), if applicable, to demonstrate background and experience relevant to their role in the proposed research project.
  - **Key Personnel Previous/Current/Pending Support (no page limit):** Upload as “Support\_LastName.pdf”.
    - For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
    - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.
- (e) Research & Related Budget:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), and for intramural submissions, refer to the General Application Instructions, Section V.A.(e), for detailed instructions.
- **Budget Justification (no page limit):** For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), Section L, for instructions. For intramural submissions, refer to General Application Instructions, Section V.A.(e), Budget Justification Instructions.
- (f) Project/Performance Site Location(s) Form:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(f), and for intramural submissions, refer to the General Application Instructions, Section V.A.(f), for detailed instructions.
- (g) Research & Related Subaward Budget Attachment(s) Form (if applicable, Extramural Submissions Only):** Refer to the General Application Instructions, Section IV.B.(g), for detailed instructions.
- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form and upload through Grants.gov.
  - **Intramural DOD Subaward:** Complete a separate “[Suggested Intragovernmental/Intramural Budget Form](#)” for each intramural DOD subaward and upload as a single document titled **IGBudget.pdf** to Grants.gov as Attachment 12.

### **II.D.2.b.iii. Full Application Submission Components for the Partnering PI (if applicable)**

The application submission process for the Partnering PI uses an abbreviated full application package. Refer to the equivalent attachment above for details specific to each of the following application components.

- (a) SF424 Research & Related Application for Federal Assistance Form (*Extramural Submissions Only*):** Refer to the General Application Instructions, Section IV.B.(a), for detailed information.
- (b) Attachments:**
- **Attachment 5: Statement of Work (five-page limit):** Upload as “SOW.pdf”. Each PI must submit an identical copy of a jointly created SOW.
  - **Attachment 11: Representations (*Extramural submissions only*):** Upload as “RequiredReps.pdf”.
  - **Attachment 12: Suggested Intragovernmental/Intramural Budget Form:** Upload as “IGBudget.pdf”.
- (c) Research & Related Personal Data:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(c), and for intramural submissions, refer to the General Application Instructions, Section V.A.(c), for detailed information.
- (d) Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions, refer to the General Application Instructions, Section IV.B.(d), and for intramural submissions, refer to the General Application Instructions, Section V.A.(d), for detailed information.
- **PI Biographical Sketch (five-page limit):** Upload as “Biosketch\_LastName.pdf”.
  - **Career Initiation or Transition Partnering PI:** If the CIT PI is the *Partnering PI*, explain how their level of research support and/or publications supports their eligibility.
  - **PI Previous/Current/Pending Support (no page limit):** Upload as “Support\_LastName.pdf”.
  - **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch\_LastName.pdf”.
  - **Key Personnel Previous/Current/Pending Support (no page limit):** Upload as “Support\_LastName.pdf”.
- (e) Research & Related Budget:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), and for intramural submissions, refer to the General Application Instructions, Section V.A.(e), for detailed information.

- **Budget Justification (no page limit):** Upload as “BudgetJustification.pdf”.

*The Initiating and Partnering PI must each submit a budget and justification specific to their own portion of the efforts as part of their separate Grants.gov or eBRAP application packages. The Research & Related Budget for the Partnering PI should not include budget information for the Initiating PI, even if they are located within the same organization. Refer to [Section II.D.5, Funding Restrictions](#), for detailed information.*

- (f) **Project/Performance Site Location(s) Form:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(f), and for intramural submissions, refer to General Application Instructions, Section V.A.(f), for detailed information.
- (g) **Research & Related Subaward Budget Attachment(s) Form (if applicable, Extramural Submissions Only):** Refer to the General Application Instructions, Section IV.B.(g), for detailed information.
  - **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov.
  - **Intramural DOD Subaward:** Complete the “[Suggested Intragovernmental/Intramural Budget Form](#)” for each intramural DOD subaward and upload as a single document titled IGBudget.pdf to Grants.gov as Attachment 12.

### II.D.2.c. Applicant Verification of Full Application Submission in eBRAP

Independent of submission type, once the full application is submitted it is transmitted to and processed in eBRAP. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log into eBRAP to review, modify, and verify the full application submission. Verification is strongly recommended but not required. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in the “Full Application Files” tab in eBRAP. However, eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. *The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the full application submission deadline.* Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the end of the [application verification period](#). The full application cannot be modified once the application verification period ends.

### II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)

The applicant organization must be registered as an entity in SAM (<https://www.sam.gov/content/home>) and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the UEI generated by SAM in applications to this funding opportunity.

#### **II.D.4. Submission Dates and Times**

The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

All submission dates and times are indicated in [Section I, Overview of the Funding Opportunity](#).

#### **II.D.5. Funding Restrictions**

The maximum period of performance is **3** years.

The application's total costs budgeted for the entire period of performance should not exceed **\$1.0M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

***Career Initiation or Transition Partnering PI Option:*** The applications' total costs budgeted for the entire period of performance in the applications of the Initiating PI and the Partnering PI should not exceed **\$1.0M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

- A separate award will be made to each PI's organization.
- The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified.

For this award mechanism, direct costs must be requested for:

- Travel costs for the PI(s) to present project information or disseminate project results at one DOD Meeting (such as a PRARP In-Progress Review meeting or other appropriate DOD-sponsored meeting) during the period of performance. For planning purposes, it should be assumed that the meeting will be held in year two of the award in the National Capital Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for one investigator to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel to scientific/technical meetings



should be to present project information or disseminate project results from the PRARP Transforming Research Award.

- Costs associated with data and research resource sharing.
- Costs associated with the collaborative research approach (e.g., consultant costs, equitable participating training, capacity-building exercises, if applicable).
- Animal Costs

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Clinical trial costs

#### **II.D.6. Other Submission Requirements**

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

### **II.E. Application Review Information**

#### **II.E.1. Criteria**

##### **II.E.1.a. Peer Review**

To determine technical merit, all applications will be individually evaluated according to the following **scored criteria**, which are of *equal importance*:

- **Impact**
  - If the aims of the project are achieved, to what extent does the project robustly address an important problem or a critical barrier to progress for prevention and risk reduction?
  - To what extent does this project represent a non-incremental advance compared to the current status of the field?
  - If the aims of the project are achieved, to what extent are scientific knowledge, technical capability, clinical practice, and dementia care improved and communicated in a timely manner?
  - Are the immediate and long-term benefits of successful completion of this project impactful for persons living with TBI and/or AD/ABRD, their families, and their care partners/caregivers? Are these benefits realistic and valuable overall?
  - Were the potential issues, and strategies to overcome them, as applicable, adequately described?

- **Research Strategy and Feasibility**

- To what extent the research strategy, methods, and analyses are appropriate and feasible and provide a robust, well-designed, and culturally competent approach to non-incremental research.
- How well the statistical plan, including sample size projections and power analysis, is appropriate to meet the objectives of the study and all proposed correlative studies.
- Applicable for projects with *proposed clinical research only*:
  - Whether the application includes sufficient evidence to support successful recruitment of and/or access to study populations, data, and samples.
  - To what extent the application sufficiently ensures the study population are representative, equitable, diverse, and inclusive.
  - How well the study population represents the beneficiaries of the research.
- Applicable for projects with *proposed animal studies only*:
  - To what extent the animal study describes how and why the animal species, strain, and model(s) being used can and is necessary and appropriate address the scientific objectives of the proposed research project.
  - Whether the specific animal model is optimal to address the study aims.
  - Whether the specific animal model is relevant to human TBI and/or AD/ADRD.
  - Whether the approaches that will be undertaken to validate or corroborate findings from animal studies are relevant to human data sources/populations.
  - Whether these approaches sufficiently de-risk the possibility that the animal findings may not translate to human populations.
- How well the application acknowledges potential problem areas and provides alternative methods and approaches.

- **Research Progression**

- Whether the progression plan realistically details the study required for the immediate next step of the research.
- How well the progression plan realistically details timelines and integrates feedback from the AD/ADRD/TBI Community.
- Whether the scientific, technical, and regulatory (as applicable) requirements described are appropriate and realistic.

- How well the progression plan incorporates stakeholder input, collaboration, intellectual property, and commercialization needs, and resources, as applicable that will be used to provide continuity of research to the next stage of development.
- **Ethical Considerations (for research involving human subjects)**
  - Whether the population selected to participate in the study stands to benefit from the knowledge to be gained as a result of the proposed research.
  - How the level of risk to human subjects is minimized and how the safety monitoring and reporting are appropriate for the level of risk.
  - To what extent the proposed clinical research might affect the daily lives of the individual human subjects participating in the study.
  - To what degree the process for seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.
- **Research Team**
  - As applicable, how well the input from the Community partner(s) is meaningfully integrated and incorporated into the planning, design, execution, and dissemination of the research.
  - To what extent the background, experience, and levels of effort of the PI, Partnering PI (if applicable), and other personnel are appropriate to accomplish the proposed research project.
  - **Career Initiation or Transition Partnering PI Option:** How well the partners' combined experience and expertise will better address the research question than could be achieved through separate efforts, and how the partnership will build research capacity in the field by developing new or transitioning PIs.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Budget**
  - Whether the **total** (direct plus indirect) costs exceed the allowable total costs as published in the program announcement.
  - Whether the budget is appropriate for the proposed research.
  - For the CIT, whether the direct cost funding is equitably distributed and proportional to each individual's effort.
- **Environment**
  - To what extent the environment is appropriate for the proposed research project.

- How well the research requirements are supported by the availability and accessibility to facilities and resources.
- To what extent the quality and level of institutional support are appropriate for the proposed research project.
- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influence the review.

### **II.E.1.b. Programmatic Review**

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the priorities of the Defense Health Program and FY24 PRARP, as evidenced by the following:
  - Relative impact
  - Program portfolio balance
  - Adherence to the intent of the funding opportunity
  - Benefit to end users, including the military. Note that military is used broadly to include not only active-duty Service Members, but Veterans, their Families, and other DOD beneficiaries.

### **II.E.2. Application Review and Selection Process**

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. *The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section II.E.1.b, Programmatic Review](#).* Additional information about the two-tier process used by the CDMRP can be found at <https://cdmrp.health.mil/about/2tierRevProcess>.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and

evaluation information will not be disclosed outside the review panel. Violations of confidentiality can result in the dissolution of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to a third party is a crime in accordance with 18 USC 1905.

### **II.E.3. Integrity and Performance Information**

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in SAM.

An applicant organization may review SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

## **II.F. Federal Award Administration Information**

### **II.F.1. Federal Award Notices**

Each applicant organization and PI will receive email notification when the funding recommendations are posted to eBRAP. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the funding recommendation and review process for the PRARP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

***Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

***Intra-DOD obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.***

Funding obligated to ***intragovernmental and intramural DOD organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD), or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOD investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), Pre-Award Costs section, and for intramural submissions, refer to the General Application Instructions, Section V.A.(e), Pre-Award Costs section, for additional information about pre-award costs.

***If there are technical reporting requirement delinquencies for any existing CDMRP awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.***

#### **II.F.2. PI Changes and Award Transfers**

Unless otherwise restricted, changes in PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 7, Section F, for general information on organization or PI changes.

#### **II.F.3. Administrative and National Policy Requirements**

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 7, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 8, for general information regarding national policy requirements.

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [USAMRAA Research Terms and Conditions: Addendum to the DoD R&D Terms and Conditions](#) for further information.

Applications recommended for funding that involve animals, human data, human specimens, human subjects, or human cadavers must be reviewed for compliance with federal and DOD animal and/or human subjects protection requirements and approved by the USAMRDC Office of Human and Animal Research Oversight, prior to implementation. This administrative review requirement is in addition to the local IACUC, IRB, or Ethics Committee review. Refer to the General Application Instructions, Appendix 6, for additional information.

The PRARP requires that all TBI-related clinical research and/or clinical trials funded by this program be shared through the jointly supported DOD-National Institutes of Health Federal Interagency TBI Research Information System (FITBIR) for FY24. Recipients will be required to upload study data annually, at minimum, and in accordance with the FITBIR data submission policies. There is no fee to use FITBIR, and detailed guidance and policies, including a cost estimator tool for budgeting considerations, can be found at <https://fitbir.nih.gov>.

#### **II.F.4. Reporting**

Annual technical progress reports and quad charts as well as a final technical progress report and quad chart will be required. Annual and final technical reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

**Award Expiration Transition Plan:** An Award Expiration Transition Plan must be submitted with the final technical progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline whether and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

**PHS Inclusion Enrollment Reporting Requirement:** Enrollment reporting on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to SAM about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 8, Section B).

## **II.G. Federal Awarding Agency Contacts**

### **II.G.1. eBRAP Help Desk**

*Questions regarding program announcement content or submission requirements as well as technical assistance related to pre-application or intramural application submission:*

Phone: 301-682-5507

Email: [help@eBRAP.org](mailto:help@eBRAP.org)

### **II.G.2. Grants.gov Contact Center**

*Questions regarding Grants.gov registration and Workspace:*

Phone: 800-518-4726; International 1-606-545-5035

Email: [support@grants.gov](mailto:support@grants.gov)

## **II.H. Other Information**

### **II.H.1. Program Announcement and General Application Instructions Versions**

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 901a. The program announcement numeric version code will match the General Application Instructions version code 901.

### **II.H.2. Administrative Actions**

After receipt of full applications, the following administrative actions may occur.

#### **II.H.2.a. Rejection**

The following will result in administrative rejection of the full application:

- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Pre-application was not submitted.



### II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

### II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the full application:

- An FY24 PRARP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation, including letters of support/recommendation. *A list of the FY24 PRARP Programmatic Panel members can be found at <https://cdmrp.health.mil/prarp/panels/panels24>.*
- The application fails to conform to this program announcement description.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Applications that include names of personnel from either of the CDMRP peer or programmatic review companies. For FY24, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (<https://cdmrp.health.mil/about/2tierRevProcess>).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP.
- Applications submitted by a federal government organization (including an intramural DOD organization) may be withdrawn if (a) the organization cannot accept and execute the entirety of the requested budget in current fiscal year (FY24) funds and/or (b) the federal government organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to collaborators.
- Application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- The PI or Partnering PI (if applicable) does not meet the eligibility criteria.

- Failure to submit all associated (Initiating and Partnering PI) applications by the deadline, if applicable.
- A clinical trial is proposed.
- ***If applicable, for applications proposing clinical research:***
  - Community Collaboration Plan ([Attachment 8](#)) is missing.
  - The application does not include a minimum of one collaborative Community partner.
- ***If applicable, for applications proposing animal research:***
  - Animal Research Plan ([Attachment 9](#)) is missing.

#### **II.H.2.d. Withhold**

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

#### **II.H.2.e. Other Funding Opportunities**

The PRARP is committed to leveraging efforts with other funding organizations to accelerate progress in AD/ADRD research. At the time of funding notifications, the PRARP may inform highly rated, unfunded applicants about opportunities to provide their PRARP applications and peer review summary statements to non-governmental funders, who will determine the specific criteria for funding consideration.

### II.H.3. Full Application Submission Checklist

Full Application Components	Uploaded	
	PI/Initiating PI	Partnering PI
<b>SF424 Research &amp; Related Application for Federal Assistance</b> <i>(Extramural submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Summary (Tab 1) and Application Contacts (Tab 2)</b> <i>(Intramural submissions only)</i>	<input type="checkbox"/>	
<b>Attachments</b>		
Project Narrative – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>	
Supporting Documentation – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>	
Technical Abstract – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>	
Lay Abstract – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>	
Statement of Work – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Impact Statement – Attachment 6, upload as “Impact.pdf”	<input type="checkbox"/>	
Progression Plan – Attachment 7, upload as “Progression.pdf” <i>(if applicable)</i>	<input type="checkbox"/>	
Community Collaboration Plan – Attachment 8, upload as “Collaboration.pdf” <i>(if applicable)</i>		
Animal Research Plan – Attachment 9, upload as “Animal.pdf” <i>(if applicable)</i>	<input type="checkbox"/>	
Partnership Statement – Attachment 10, upload as “Partnership.pdf” <i>(if applicable)</i>	<input type="checkbox"/>	
Representations <i>(Extramural submissions only)</i> – Attachment 11, upload as “RequiredReps.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Suggested Intragovernmental/Intramural Budget Form <i>(if applicable)</i> – Attachment 12, upload as “IGBudget.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
<b>Research &amp; Related Personal Data</b>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Research &amp; Related Senior/Key Person Profile (Expanded)</b>	<input type="checkbox"/>	<input type="checkbox"/>
Attach PI Biographical Sketch (Biosketch_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
<b>Career Initiation or Transition Partnering PI</b>	<input type="checkbox"/>	<input type="checkbox"/>
Attach PI Previous/Current/Pending Support (Support_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person	<input type="checkbox"/>	<input type="checkbox"/>

Full Application Components	Uploaded	
	PI/Initiating PI	Partnering PI
Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person	<input type="checkbox"/>	<input type="checkbox"/>
<b>Research &amp; Related Budget</b> ( <i>Extramural submissions only</i> ) Include budget justification	<input type="checkbox"/>	<input type="checkbox"/>
<b>Budget</b> ( <i>Intramural submissions only</i> ) Include budget justification	<input type="checkbox"/>	<input type="checkbox"/>
<b>Project/Performance Site Location(s) Form</b>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Research &amp; Related Subaward Budget Attachment(s) Form</b> ( <i>if applicable</i> )	<input type="checkbox"/>	<input type="checkbox"/>

## APPENDIX 1: ACRONYM LIST

AD/ADRD	Alzheimer’s Disease and Related Dementias
CAB	Community Advisory Board
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CIT	Career Initiation or Transition Partnering Option
DOD	Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
eBRAP	Electronic Biomedical Research Application Portal
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
IACUC	Institutional Animal Care and Use Committee
IRB	Institutional Review Board
LEC	Lived Experience Consultant
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PRARP	Peer Reviewed Alzheimer’s Research Program
RPPR	Research Performance Progress Report
SAM	System for Award Management
SOW	Statement of Work
STEM	Science, Technology, Engineering, and/or Mathematics
TBI	Traumatic Brain Injury
TrRA	Transforming Research Award
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USAMRAA	U.S. Army Medical Research Acquisition Activity
USAMRDC	U.S. Army Medical Research and Development Command
USC	United States Code
VA	U.S. Department of Veterans Affairs